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Background: Expression and activity of heparanase, an endoglycosidase that cleaves heparan sulfate (HS) side chains
of proteoglycans, is associated with progression and poor prognosis of many cancers which makes it an attractive drug
target in cancer therapeutics.
Methods: In the present work, we report the in vitro screening of a library of 150 small molecules with the
scaffold bearing quinolones, oxazines, benzoxazines, isoxazoli(di)nes, pyrimidinones, quinolines, benzoxazines,
and 4-thiazolidinones, thiadiazolo[3,2-a]pyrimidin-5-one, 1,2,4-triazolo-1,3,4-thiadiazoles, and azaspiranes against
the enzymatic activity of human heparanase. The identified lead compounds were evaluated for their
heparanase-inhibiting activity using sulfate [35S] labeled extracellular matrix (ECM) deposited by cultured
endothelial cells. Further, anti-invasive efficacy of lead compound was evaluated against hepatocellular
carcinoma (HepG2) and Lewis lung carcinoma (LLC) cells.
Results: Among the 150 compounds screened, we identified 1,2,4-triazolo-1,3,4-thiadiazoles bearing
compounds to possess human heparanase inhibitory activity. Further analysis revealed 2,4-Diiodo-6-(3-
phenyl-[1, 2, 4]triazolo[3,4-b][1, 3, 4]thiadiazol-6yl)phenol (DTP) as the most potent inhibitor of heparanase
enzymatic activity among the tested compounds. The inhibitory efficacy was demonstrated by a
colorimetric assay and further validated by measuring the release of radioactive heparan sulfate
degradation fragments from [35S] labeled extracellular matrix. Additionally, lead compound significantly
suppressed migration and invasion of LLC and HepG2 cells with IC50 value of ~5 μM. Furthermore, molecular docking
analysis revealed a favourable interaction of triazolo-thiadiazole backbone with Asn-224 and Asp-62 of the enzyme.
Conclusions: Overall, we identified biologically active heparanase inhibitor which could serve as a lead structure in
developing compounds that target heparanase in cancer.
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The extracellular matrix (ECM) plays a prime role in
maintaining the architecture and integrity of organs and
tissues [1]. Collagen, fibronectin, laminin and several
growth factors and cytokines interact with heparan sul-
fate proteolglycans (HSPGs) in the ECM and cell surface
to maintain cellular framework and function [2, 3].
Heparanase is the predominant endoglycosidase that cat-
alyzes the cleavage of heparan sulfate (HS) polysacchar-
ide chains in HSPGs into smaller fragments and thereby
modulates the functions of HS [4–10]. Heparanase
degrades the linkage between glucuronic acid and N-
sulfo glucosamine residues at restricted sites of HS
yielding fragments of 4-7 kDa [6]. Heparanase activity
contributes to disassembly and remodeling of basement
membrane and ECM resulting in upregulated cell migra-
tion and invasion and release of HS-bound growth- and
angiogenesis- promoting factors [7–9]. Notably, elevated
levels of heparanase are positively correlated with trig-
gered expression of MMP-9, hepatocyte growth factor
(HGF) and vascular endothelial growth factor (VEGF)
that are entangled with cancer progression [11–13]. To-
gether, these and other results critically support the in-
timate involvement of heparanase in tumor progression
and encourage the development of heparanase inhibitors
as anti-cancer therapeutics [14–16].
Several heparin/HS mimetics were demonstrated as
heparanase inhibitors and some have entered clinical
trials [8, 15], among these are Muparfostat (PI-88),
Roneparstat (SST0001), PG545, and necuparanib (M402)
[8, 15]. Muparfostat is a mixture of sulfated di- to hexa-
saccharides which progressed to Phase III clinical trial in
post-resection hepatocellular carcinoma. It displayed sig-
nificant hematologic side effects when administered with
docetaxel [17, 18]. PG545, a fully sulfated hexasaccharide
conjugated with a lipophilic moiety, is a dual inhibitor of
heparanase and angiogenesis, currently in phase-I
clinical trials in patients with advanced solid tumors
([19], https://clinicaltrials.gov/ct2/show/NCT02042781).
Roneparstat, N-acetylated glycol-split heparin, is in
phase I clinical trial in myeloma patients (https://clinical
trials.gov/ct2/show/study/NCT01764880, [20]. Similarly,
necuparanib (glycol-split low molecular weight heparin)
is in phase-I/II trial for pancreatic cancer in combination
with nab-paclitaxel and gemcitabine (https://clinicaltrials
.gov/ct2/show/NCT01621243, [21]). Given the diverse
effects of heparin-like compounds, these studies indicate
the significance of designing chemically novel, highly
selective and biologically active heparanase inhibitors to
potently target various types of cancers and possibly in-
flammatory diseases [8, 15]. Synthesis of heparanase-
inhibiting small molecules has been reported [8, 16, 22],
but none was advanced to preclinical and clinical studies
[8]. We have previously reported the synthesis of variousheterocylces with good anticancer activity [23–29]. The
current saccharide-based compounds are not specific for
heparanase leaving open the question as to how much of
their anti-tumor effect is due specifically to blocking hepar-
anase activity. Herein, we screened 150 small molecules
with the scaffold bearing quinolones, oxazines, benzoxa-
zines, isoxazoli(di)nes, pyrimidinones, quinolines, benzoxa-
zines, and 4-thiazolidinones, thiadiazolo[3,2-a]pyrimidin-5-
one, 1,2,4-triazolo-1,3,4-thiadiazoles, and azaspiranes for in-
hibition of human heparanase enzymatic activity. Selected
molecules were tested for inhibition of cell migration and
invasion. The most effective compound was examined for
putative binding modes against the target enzyme using
molecular docking analysis.
Methods
All solvents were of analytical grade and reagents were
purchased from Sigma-Aldrich. 1H and 13C NMR spec-
tra were recorded on a Varian and Bruker WH-200
(400 MHz) spectrometer in CDCl3 or DMSO-d6 as solv-
ent, using TMS as an internal standard and chemical
shifts are expressed as ppm. Mass spectra were deter-
mined on a Shimadzu LC-MS. High resolution mass
spectra were determined on a Bruker Daltonics instru-
ment. The elemental analyses were carried out using an
Elemental Vario Cube CHNS rapid Analyzer. The pro-
gress of the reaction was monitored by TLC pre-coated
silica gel G plates.
Heparanase
Active heparanase was produced in HEK 293 cells stably
transfected with the human heparanase gene construct
in the mammalian pSecTag vector. The enzyme was
purified and kindly provided by Dr. Yi Zhang (Eli Lilly
and Company, New York, NY) [30].
Cells
Mouse Lewis lung carcinoma (LLC; ATCC Cat. number:
CRL-1642), human lung carcinoma (HCC827; ATCC
Cat. number: CRL-2868), and human hepatocellular car-
cinoma (HepG2, Hep3B; ATCC Cat. number: HB-8065
and HB-8064, respectively) cell lines were obtained from
the American Type Culture Collection and working
stocks did not exceed four passages. The cell lines have
recently been tested for mycoplasma contamination and
authenticated using the Promega PowerPlex 16 HS kit.
Cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with glutamine, pyru-
vate, antibiotics and 10% fetal calf serum in a humidified
atmosphere containing 5% CO2 at 37 °C.
Real-time PCR
Total RNA was extracted with TRIzol (Sigma) and RNA
(1 μg) was amplified using one step PCR amplification
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instructions. The PCR primer sets utilized were: i) mouse
heparanase - Forward: 5′ TTTGCAGCTGGCTTTATG
TG 3′, Reverse: 5′ GTCTGGGCCTTTCACTCTTG 3′
(207 nucleotides); ii) mouse GAPDH - Forward: 5′ AGAA
CATCATCCCTGCATCC 3′, Reverse: 5′ AGCCGTATTC
ATTGTCATACC 3′ (348 nucleotides); iii) human hepara-
nase - Forward: 5′ CCAGCCGAGCCACATCGCTC 3′,
Reverse: 5′ ATGAGCCCCAGCCTTCTCCAT 3′ (550
nucleotides); iv) human GAPDH - Forward: 5′ ACAGTTC
TAATGCTCAGTTGCTC 3′; Reverse: 5′ TTGCCTCATC
ACCACTTCTATT 3′ (360 nucleotides).
Preparation of Sulphated Ceria
Hydrous cerium oxide was prepared by the hydrolysis of
cerium (III) nitrate hexahydrate with 1:1 ammonia. Cer-
ium (III) nitrate was dissolved in double distilled water.
To this clear solution, dilute (1:1) aqueous ammonia was
added drop-wise from a burette with vigorous stirring
until the pH of the solution reached 8.
The solution was boiled for 15 min and allowed to
stand overnight. The mother liquor was then decanted
and the precipitate was washed several times with dis-
tilled water till it is completely free of nitrate ions which
was confirmed by brown ring test. The precipitate was
filtered and dried overnight at 383 K for 16 h. The hy-
droxide obtained was sieved to get particles of 75-
100 μm mesh size and immersed in (1:1) H2SO4 solution
(2 mL/g) and subjected to stirring for 4 h. Excess water
was evaporated and the resulting sample was oven dried
at 383 K for 16 h, calcined at 823 K for 5 h and stored
in vacuum desiccator.
General procedure for Microwave synthesis of 4-amino-5-
phenyl-4 h-1,2,4-triazole-3-thiol (2)
A mixture of methylbenzoate (1 mmol) and hydrazine hy-
drate (1 mmol) in 20 mL ethanol was irradiated in micro-
wave at 700 W in a specially designed Teflon vessel
containing lead acetate, until all the starting material was
consumed (1-2 min, as monitored by TLC). To the above
mixture (0.006 mmol) of KOH, CS2 (1 mmol) was added
and further irradiated at 700 W for 1 min. Finally, hydra-
zine hydrate (2 mmol) was added drop wise to the above
mixture and continued the irradiation at 700 W until a
white solid appeared at the bottom (2-3 min). The lead
acetate worked as a trap for H2S that was evolved during
reaction. The solid obtained was dissolved in water (15-
20 mL) and acidified with conc. HCl. The separated solid
was filtered, dried and recrystallized to obtain pure 4-
amino-5-phenyl-4 h-1,2,4-triazole-3-thiol. Yield 78%, m.p.
232-234 °C; IR (KBr) γ/cm
−1: 3310.07 (NH2 stretch),
3071.36 (aromatic CH stretch), 1472.38 (tautomeric
C = S). 1H NMR: (400 MHz, DMSO-d6). δ:7.6-7.5 (m, 2H,
ArH), 7.34-7.2 (m, 3H, ArH), 5.14 (s, 2H, NH2).General procedure for the synthesis of 6-substituted-3-
phenyl-(1,2,4)-triazolo(3,4-b)(1,3,4-thiadiazole (4a-4 h) by
using SCe
To a mixture of 4-amino-5-phenyl-4 h-1,2,4-triazole-3-
thiol (1 mmol) and (3a-h) (1 mmol) in DMF (10 mL),
SCe (20 mol%) and POCl3 (0.1 mmol) were added. The
reaction mixture was refluxed for 10 h. Completion of
the reaction was monitored by TLC and the catalyst was
filtered and washed with water. Solvent was removed
under reduced pressure and crushed ice was added to
the concentrated mass. The pH of reaction mixture was
adjusted to 8.0 using K2CO3 and KOH. The solid ob-
tained was separated by filtration, washed with excess
water, dried and recrystallized using appropriate solvent.
General procedure for the synthesis of 2-hydroxy-3,5-
diiodo-N-(3-phenyl-5-thioxo-1H-1,2,4-triazol-4(5H)-yl)benza-
mide (5a) and 2-hydroxy-5-iodo-N-(3-phenyl-5-thioxo-1H-
1,2,4-triazol-4(5H)-yl)benzamide (5b)
To 3a (1 eq) in DMF, EDC (1.1 eq) and HOBt (1.1 eq)
was added and stirred at room temperature for 30 min.
It was followed by the addition of amine (2) and stirred
for 2 h. After completion of the reaction, it was diluted
with water and the obtained solid was filtered and re-
crystallized in appropriate solvent.
2,4-Diiodo-6-(3-phenyl-[1, 2, 4]triazolo[3,4-b][1, 3,
4]thiadiazol-6yl)phenol (4a, DTP)
Yellow colored solid; 1H NMR (400 MHz, DMSO-d6)
8.37-8.35 (d, 2H), 8.26 (s, 1H), 7.85 (s, 1H), 7.69-7.63 (m,
2H), 7.54-7.52 (d, 1H), 4.92 (s, 1H); 13C NMR (DMSO-
d6); 165.53, 154.53, 149.29, 148.83, 140.98, 137.51,
133.83, 132.45, 129.11, 128.64, 123.10, 122.44, 120.72,
96.18, 85.11; HRMS Calcd 568.840; Found: 568.840
(M + Na)+; Anal. Calcd for C15H8I2N4OS: C, 32.99; H,
1.48; N, 10.26; Found: C, 33.00; H, 1.49; N, 10.28.
6-(4-(1H-Imidazol-1-yl)phenyl)-3-phenyl-[1, 2, 4]triazolo[3,4-
b][1, 3, 4]thiadiazole (4b)
Pale yellow colored solid; 1H NMR (400 MHz, DMSO-
d6) δ: 8.46-8.44 (d, 2H), 7.81-7.77 (m, 2H), 7.53-7.49 (m,
3H), 7.39-7.34 (m, 3H), 7.27-7.24 (m, 2H); 13C NMR
(DMSO-d6); 161.55, 149.29, 148.53, 140.98, 137.18,
137.11, 133.83, 132.48, 131.97, 129.11, 128.64, 128.18,
123.10, 122.43, 120.27; LCMS (MM:ES + APCI) 345.2
(M + H)+. Anal. Calcd for C18H12N6S: C, 62.77; H, 3.51;
N, 24.40; Found: C, 62.79; H, 3.53; N, 24.43.
4-Iodo-2-(3-phenyl-[1, 2, 4]triazolo[3,4-b][1, 3, 4]thiadiazol-
6-yl)phenol (4c, ITP)
Yellow colored solid; 1H NMR (400 MHz, DMSO-d6) δ:
8.44-8.42 (d, 2H), 8.08-8.06 (d, 2H), 8.02-8.00 (m, 1H),
7.95-7.91 (m, 1H), 7.71 (s, 1H), 7.16-7.14 (d, 1H), 4.92 (s,
1H); 13C NMR (DMSO-d6) δ: 164.19, 159.73, 152.02,
Baburajeev et al. BMC Cancer  (2017) 17:235 Page 4 of 14147.46, 138.26, 133.27, 131.64, 129.40, 127.70, 124.93,
120.48, 119.82, 118.66, 88.23; HRMS Calcd 442.943; Found:
442.943 (M + Na)+; Anal. Calcd for C15H9IN4OS: C, 42.87;
H, 2.16; N, 13.33; Found: C, 42.89; H, 2.17; N, 13.35.
6-(((R)-Tetrahydro-2H-pyran-2-yl)(phenyl)methyl)-3-phenyl-
[1, 2, 4]triazolo[3,4-b][1, 3, 4]thiadiazole (4d)
White colored solid; 1H NMR (400 MHz, DMSO-d6) δ:
8.25-8.16 (d, 2H), 8.06 (m, 1H), 7.78-7.76 (m, 1H), 7.62-
7.60 (m, 1H), 7.27-7.15 (m, 4H), 4.58-4.53 (m, 2H), 3.88-
3.84 (m, 2H), 1.78-1.73 (m, 4H), 1.50-1.45 (m, 2H); 13C
NMR (DMSO-d6) δ: 164.56, 149.30, 143.93, 141.04,
137.49, 132.82, 132.41, 130.23, 129.10, 128.10, 120.70,
80.11, 71.09, 43.59, 30.41, 30.33, 21.48; LCMS
(MM:ES + APCI) 377.2 (M + H)+; Anal. Calcd for
C21H20N4OS: C, 67.00; H, 5.35; N, 14.88; Found: C,
67.02; H, 5.37; N, 14.90.
2-(3-Phenyl-[1, 2, 4]triazolo[3,4-b][1, 3, 4]thiadiazol-6yl)-1-p-
tolylethanone (4e)
White colored solid; 1H NMR (400 MHz, DMSO-d6) δ:
8.43-8.41 (m, 2H), 8.03-7.99 (m, 3H), 7.92 (m, 1H), 7.69
(m, 1H), 7.40-7.38 (m, 2H), 4.1 (s, 2H), 2.42 (m, 3H); 13C
NMR (DMSO-d6) δ:192.83, 164.18, 159.42, 151.99,
146.87, 137.47, 132.28, 130.26, 125.66, 123.38, 121.01,
120.89, 48.13, 21.13; HRMS Calcd 357.078; Found:
357.078 (M + Na)+. Anal. Calcd for C18H14N4OS: C,
64.65; H, 4.22; N, 16.75; Found: C, 64.67; H, 4.25; N,
16.77.
6-(3-4-Dimethoxybenzyl)-3-phenyl-[1, 2, 4]triazolo[3,4-b][1,
3, 4]thiadiazole (4f)
Yellow colored solid; 1H NMR (400 MHz, DMSO-d6) δ:
8.2 (d, 2H), 7.6-7.4 (m, 3H), 7.0 (s, 1H), 6.9 (d, 2H), 4.4
(s, 2H), 3.8 (s, 6H); LCMS (MM:ES + APCI) 353.2
(M + H)+; Anal.Calcd for C18H16N4O2S: C, 61.35; H,
4.58; N, 15.90; Found: C, 61.39; H 4.59; N, 15.93.
3-(3-Phenyl–[1, 2, 4]triazolo[3,4-b][1, 3, 4]thiadiazol-6-yl-
)phenol (4 g)
White colored solid; 1H NMR (400 MHz, DMSO-d6) δ:
8.32-8.31 (m, 2H), 8.13 (s, 1H), 7.94-7.87 (m, 3H), 7.65-
7.59 (m, 2H), 7.46 (m, 1H), 4.91 (s, 1H); LCMS
(MM:ES + APCI) 295.2 (M + H)+; Anal. Calcd for
C15H10N4OS: C, 61.21; H, 3.42; N, 19.04; Found: C,
61.23; H, 3.44; N, 19.07.
3-Phenyl-6-styryl-[1, 2, 4]triazolo[3,4-b][1, 3, 4]thiadiazole
(4 h)
White colored solid; 1H NMR (400 MHz, DMSO-d6) δ:
8.25-8.22(d, 2H), 7.92-7.87 (m, 2H), 7.73-7.55 (m, 4H),
7.32-7.26 (m, 2H), 6.45-6.42 (m, 2H); 13C NMR (DMSO-
d6) δ: 164.84, 159.58, 153.39, 145.42, 139.89, 131.08,
131.04, 130.53, 130.42, 130.31, 129.09, 125.84, 125.47,118.08, 116.18, 115.90; HRMS Calcd 327.067; Found:
327.067 (M + Na)+; Anal. Calcd for C17H12N4S: C, 67.O8;
H, 3.97; N, 18.41; Found: C, 67.09; H, 3.99; N, 18.44.
2-Hydroxy-3,5-diiodo-N-(3-phenyl-5-thioxo-1H-1,2,4-triazol-
4(5H)-yl)benzamide (5a, HTP)
Pale yellow colored solid; 1H NMR (400 MHz, DMSO-
d6) δ: 14.64 (s, NH), 12.30 (s, NH), 8.48 (s, 1H), 8.40 (s,
1H), 8.24-8.15 (m, 3H), 7.81-7.78 (m, 2H), 4.73 (s, 1H);
13C NMR (DMSO-d6) δ:181.47, 173.23, 153.47, 147.94,
145.12, 136.38, 134.36, 131.13, 129.09, 128.78,
128.21, 126.02, 125.58, 90.79, 72.33; HRMS Calcd
586.851; Found: 586.851 (M + Na)+; Anal.Calcd for
C15H10I2N4O2S: C, 31.94; H, 1.79; N, 9.93; Found: C,
31.96; H, 1.81; N, 9.93.
2-Hydroxy-5-iodo-N-(3-phenyl-5-thioxo-1H-1,2,4-triazol-
4(5H)-yl)benzamide (5b)
Pale yellow colored solid; 1H NMR (400 MHz,
DMSO-d6) δ: 12.5 (s, NH), 8.5 (s, 1H), 8.4 (m, 1H),
8.1 (m,1H), 7.8 (m, 3H), 7.6 (m,1H), 4.6 (s, 1H);
LCMS (MM:ES + APCI) 438.4 (M + H)+; Anal. Calcd
for C15H11IN4O2S: C, 41.11; H, 2.53; N, 12.78; Found:
C, 41.12; H, 2.56; N, 12.80.
Spectral data of the compounds are presented in
Additional file 1: Figure S1.
Colorimetric heparanase assay
The assay, carried out in 96 well microplates, measures
the appearance of the disaccharide product of
heparanase-catalyzed fondaparinux cleavage, colorimet-
rically using the tetrazolium salt WST-1 [31]. Briefly,
assay solutions (100 μL) are composed of 40 mM so-
dium acetate buffer (pH 5.0) and 100 mM fondaparinux
(Arixtra) with or without increasing concentrations of
inhibitor. Recombinant heparanase was added to a final
concentration of 140 pM, to start the assay. The plates
are incubated at 37 °C for 18 h and the reaction is
stopped by the addition of 100 μL solution containing
1.69 mM 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-
tetrazolio]-1,3-benzene disulfonate (WST-1) in 0.1 M
NaOH. The plates are developed at 60 °C for 60 min,
and the absorbance is measured at 584 nm. In each
plate, a standard curve constructed with D-galactose as
the reducing sugar standard is prepared in the same buf-
fer and volume over the range of 2–100 μM [31].
ECM degradation heparanase assay
The semi-quantitative heparanase assay was performed
as described previously [32, 33]. Briefly, metabolically
sulfate [35S] labeled ECM deposited by cultured endo-
thelial cells and coating the surface of 35 mm tissue cul-
ture dishes [33], is incubated (3 h, 37 °C, pH 6.0, 1 mL
final volume) with recombinant human heparanase
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small molecules. The ECM was also incubated (24 h,
37 °C, pH 6.0) with cell lysates (200 μg protein/dish)
prepared by 3 cycles of freeze and thaw in reaction buf-
fer, as described [32]. To evaluate the occurrence of
proteoglycan degradation, the incubation medium is col-
lected and applied for gel filtration on Sepharose 6B col-
umns (0.9 × 30 cm). Fractions (0.2 mL) are eluted with
PBS and counted for radioactivity. The excluded volume
(Vo) is marked by blue dextran and the total included
volume (Vt) by phenol red. Degradation fragments of
HS side chains are eluted from Sepharose 6B at
0.5 < Kav < 0.8 (fractions 12-25) [32].In vitro cytotoxicity assay
The antiproliferative effect of the compounds against
LLC (Lewis lung carcinoma) and HepG2 (hepatocellular
carcinoma) cells was determined by the MTT dye up-
take method as described previously [34–36]. Briefly,
cells (2.5 × 104/mL) were incubated in triplicate in a 96-
well plate, in the presence of varying concentrations of
test compounds at a volume of 0.2 mL, for different time
intervals at 37 °C. Thereafter, 20 μL MTT solution
(5 mg/mL in PBS) was added to each well. After 2 h in-
cubation at 37 °C, 0.1 mL lysis buffer (20% SDS, 50%
dimethylformamide) was added and incubated for 1 h at
37 °C, and the optical density (OD) at 570 nm was mea-
sured using a plate reader.In vitro trans-well invasion/migration assay
Invasion of cells (LLC, HepG2) across a Matrigel™
coated membrane or migration through control un-
coated inserts was assessed using 24-well plates (BD Bio-
sciences, 8 μm pore size, insert size: 6.4 mm) according
to the manufacturer’s protocol and as described earlier
[37–39]. Briefly, single cell suspensions (1 × 106 cells/
mL) were prepared by detaching and resuspending the
cells in DMEM containing 0.1% BSA. Before adding the
cells, the chambers were rehydrated for 2 h in an
incubator at 37 °C. The lower chambers were filled with
600 μL DMEM containing chemo-attractant (10% FBS).
After seeding the cells (2 × 105 in 200 μL of serum-free
medium) into the upper chamber of triplicate wells withScheme 1 Schematic representation of new heparanase inhibitors used in
700 watt; ii) SCe (20 mol%), DMF, 10 hor without increasing concentrations of compounds, the
chambers were incubated for 24 h (LLC) and 48 h
(HepG2) at 37 °C. The non-invaded cells were removed
from the upper surface of the membrane by scrub-
bing and cells that migrated through the filter were
fixed, stained with Diff Quick solution, counted by
examination of at least five microscopic fields and
photographed.
Results
Chemical synthesis and characterization
In recent years, solid acid catalysts have gained consider-
able attention due to their high efficiency, eco-friendly,
longer catalyst life, negligible equipment corrosion and
their reusability. In present work we report the synthesis
of novel 1,2,4-triazolo-1,3,4-thiadiazoles bearing com-
pounds via sulfated ceria mediated cycalization reaction
[40–42]. Initially we synthesized the sulphated ceria
(SCe) catalyst as reported previously [43]. The powdered
X-ray diffraction (PXRD), Burner- Ememett-Teller (BET)
and Scanning Electron microscope patterns of SCe
matched with the standard material.
The experimental strategy for the synthesis of starting
material 4-amino-5-phenyl-4 h-1,2,4-triazole-3-thiol (2)
was achieved by Microwave method as reported recently
(Scheme 1, i) [36]. In order to synthesize the novel
1,2,4-triazolo-1,3,4-thiadiazoles, we focused on the effi-
ciency of SCe in cyclisation reaction. To optimise the re-
action conditions, we attempted reaction in the
combination of 2 and 3-oxo-3-(p-tolyl)propanoic acid
(3e) as a model reaction in different concentrations of
SCe and the results are summarised in Additional file 1:
Table S1. The ideal system for the cyclization was found
to be 20 mol% of SCe in DMF (Additional file 1: Table
S1, entry 8). We also observed incomplete conversions,
when SCe was lower than 20 mol%, despite of longer
reaction time. From the above reaction, we examined
the generality of method by synthesizing series of 1,2,4-
triazolo-1,3,4-thiadiazoles molecules (Scheme 1, ii).
Influence of SCe on cyclization
The modification of SCe with anions such as sulphate
ions forms a super acidic catalyst which effectively catal-
yses the cyclization. Majority of reactions completedthis study. i) hydrazine hydrate, ethanol, MWI; CS2 and KOH, 5-6 min at
Scheme 2 Plausible mechanism of cyclization and synthesis of title compounds
Baburajeev et al. BMC Cancer  (2017) 17:235 Page 6 of 14within 10 h and undissolved SCe was separated by sim-
ple filtration and finally furnished the product in good
yield (Additional file 1: Table S1).Plausible mechanism
The First step involves the protonation of acid followed
by dehydration and simultaneous attack of nitrogen lone
pair to the electron deficient acylium ion to form an
intermediate. In the second step, the intermediate
undergoes neighboring group participation with nucleo-
philic sulphur, which leads to the formation of C-S bond
by the elimination of water molecule (Scheme 2). Finally,
deprotonation results in the formation of the title prod-
ucts (4a-h).Scheme 3 Synthetic scheme for the preparation of N-amino-triazole-
amides. i) HOBt/EDC, DMF, RT, 2 h. R1 = 3a, 3cRe-usability of acid catalyst system
Experiment was performed to study the recyclability of
the SCe system employing 2 with 3e to yield compound
4e (Scheme 1). After each run, catalyst was removed by
filtration from the reaction mixture, washed thoroughly
with acetone, dried and activated at 823 K and taken for
next cycle. We observed significant reduction in the
yield of the product after second run (Additional file 1:
Table S2). It is important to note that this system is
recyclable twice with the isolated yields above 70%.
Further, we synthesized the amide derivatives of 2 with
corresponding mono and di iodo salicylic acid (3a and
3c) via HOBt/EDC amide formation reactions (Scheme
3) which resulted in the products 2-hydroxy-3,5-diiodo-
N-(3-phenyl-5-thioxo-1H-1,2,4-triazol-4(5H)-yl)benzamide
(5a) and 2-hydroxy-5-iodo-N-(3-phenyl-5-thioxo-1H-1,2,4-triazol-4(5H)-yl)benzamide (5b). The compounds obtained
were characterized by 1H NMR, 13C NMR, and mass spec-
tral analysis (Additional file 1: Figure S1 – Spectral data).
Detailed chemical characterization of the newly synthesized
compounds is provided in the ‘methods’ section.In vitro screening of the small molecule library for
inhibition of the catalytic activity of human heparanase
Initially we screened the entire library of small molecules
with diverse structures for their in vitro inhibitory activ-
ity against recombinant human heparanase at different
concentrations up to 20 μg/mL. We used a 96-well
based colorimetric assay that measures the ability of re-
combinant heparanase to degrade fondaparinux (heparin
derived pentasaccharide) in solution [31]. The assay
measures the appearance of a disaccharide product of
fondaparinux cleavage, using the tetrazolium salt WST-1
[31]. Compounds bearing triazolo-thiadiazole backbone
displayed significant inhibitory activity, 2,4-Diiodo-6-(3-
phenyl-[1, 2, 4]triazolo[3,4-b][1, 3, 4]thiadiazol-6yl)phe-
nol (DTP) being the lead and consistently active
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5-thioxo-1H-1,2,4-triazol-4(5H)-yl)benzamide (HTP)
and 4-iodo-2-(3-phenyl-[1, 2, 4]triazolo[3,4-b][1, 3,
4]thiadiazol-6-yl)phenol (ITP) (Fig. 1a).
In order to better resemble the in vivo situation, we
applied as substrate metabolically sulfate [Na2
35SO4] la-
beled extracellular matrix (ECM) deposited by cultured
endothelial cells [32]. This naturally produced substrate
closely resembles the subendothelial basement mem-
brane in its composition, biological function and barrier
properties. Years of experience revealed that compounds
that effectively inhibit the enzyme in this assay are also
effective in preclinical animal models [20, 44, 45]. This
semi-quantitative assay measures release of radioactive
heparan sulfate (HS) degradation fragments from an in-
soluble extracellular matrix (ECM) that is firmly bound
to a culture dish [32, 33]. Briefly, the ECM substrate is
incubated with recombinant human heparanase in the
absence and presence of candidate small molecules. The
incubation medium is collected and subjected to gelFig. 1 a Screening of compounds for inhibition of heparanase enzymatic
activity applying the Fondaparinux heparanase assay. PC, positive control
= N-(4-{[4-(1H-Benzoimidazol-2-yl)-arylamino]-methyl}-phenyl)-benzamide
[22]. b Lead molecules which exhibited inhibitory activity against human
heparanase were validated using a semi-quantitative assay that measures
release of radioactive heparan sulfate fragments from an insoluble
extracellular matrix as described in ‘Methods’ section. Briefly, sulfate [35S]
labeled ECM was incubated (6 h, 37 °C, pH 6.0) with recombinant human
heparanase (200 ng/mL) in the absence and presence of 10 μg/mL of the
test compounds. Sulfate labeled material released into the incubation
medium was subjected to gel filtration on Sepharose 6B. Compound DTP
effectively inhibited the cleavage and release of heparan sulfate
degradation fragmentsfiltration on Sepharose 6B. Degradation fragments of
heparan sulfate side chains are eluted at 0.5 < Kav < 0.8,
whereas nearly intact HSPG is eluted next to the void
volume [32]. As demonstrated in Fig. 1b, compound
DTP (10 μg/mL) completely inhibited the release of hep-
aran sulfate degradation fragments. The other structural
analogs were less effective (not shown). Thus, we have
identified heparanase-inhibiting lead compound from a
random screen of bioactive compounds.
Heparanase activity in various hepatocellular and lung
carcinoma cell lines
Heparanase expression (RT-PCR) (Fig. 2a) and enzym-
atic activity (Fig. 2b) were examined in various hepato-
cellular carcinoma (human HepG2, Hep3B) and lung
carcinoma (human HCC827, mouse LLC) cell lines. A
relatively low expression level and enzymatic activity
were noted in HepG2 cells as compared to the other cell
lines which exhibited moderate-high heparanaseFig. 2 Heparanase expression and activity in various hepatocellular and
lung carcinoma cell lines. Mouse Lewis lung carcinoma (LLC), human
lung carcinoma (HCC827 = HCC), and human hepatocellular carcinoma
(HepG2, Hep3B) cells maintained in culture were subjected to RT-PCR (a)
and heparanase activity (b) assays, as described in ‘Methods’
Table 1 Characterization and anti-proliferative activity of the newly synthesized small molecules that are used for the in vitro heparanase
enzyme inhibition studies
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carcinoma and LLC mouse Lewis lung carcinoma cells
lines were selected for further experimentation, represent-
ing human and mouse cells expressing low (HepG2) and
moderate-high (LLC) enzymatic activity, respectively.
DTP suppresses the proliferation of LLC and HepG2 cells
Given the overexpression of heparanase in hepatocellu-
lar and lung carcinoma cancer cell lines, we next ana-
lyzed the effect of triazolo-thiadiazoles on LLC (Lewis
Lung carcinoma) and HepG2 (hepatocellular carcinoma)
cell proliferation using the MTT assay [46–48].
Paclitaxel and DMSO were used as reference drug and
vehicle control, respectively. Among the tested triazolo-
thiadiazoles, DTP was found to exert an antiproliferative
effect with IC50 value of 11.9 and 8.3 μM against LLC
and HepG2, respectively (Table 1). Thus, structure activ-
ity relationship of the lead anticancer agent revealed that
phenolic and iodine substituents on the core triazolo-
thiadiazole nucleus were found to increase the inhibitory
activity towards the proliferation of cancer cells. Not-
ably, the exo-conjugation to the triazolo-thiadiazole
core structure also enhances the cytotoxicity. TheFig. 3 Effect of DTP on LLC cell migration and Invasion. LLC cells were plated
Matrigel coat) (a) and invasion (with Matrigel coat) (b) were measured as des
heparin (100 μg/mL) on cell migration and invasion is demonstrated by repre
graphs. Data are represented as mean ± S.E. *P < 0.1; **P < 0.05. ***P < 0.01hydrophobic substituents on the core structure were
found to be ineffective against proliferation of cancer
cells.
DTP inhibits migration and invasion of LLC cells
The involvement of heparanase in cancer metastasis is
clearly demonstrated in various types of cancer [9, 14, 32].
We investigated the effect of DTP on LLC and HepG2 cell
migration and invasion applying trans-well filters (8 μM
pore size) that were either uncoated or coated with Matri-
gel, respectively. LLC (Fig. 3) and HepG2 (Fig. 4) cells mi-
grated through uncoated filters and invaded through
Matrigel in response to stimulation with FBS. DTP
significantly suppressed cell migration (Figs. 3a and
4a) and invasion (Figs. 3b and 4b) in a dose
dependent manner, yielding nearly 50% inhibition at
5 μM. This effect is likely attributed to inhibition of
heparanase enzymatic activity by DTP. Heparin was
used as positive control.
Rationalizing SAR trends via protein-ligand interactions
In order to perform virtual screening, a recently pub-
lished X-ray crystal structure for human heparanase wason BD BioCoat™ chambers (BD Biosciences) and cell migration (without
cribed in ‘Methods’. The effect of lead compound DTP (1–10 μM) or
sentative photomicrographs (magnification: ×10) and the respective bar
Fig. 4 Effect of DTP on HepG2 cell migration and Invasion. HepG2 cells were plated on BD BioCoat™ chambers (BD Biosciences) and cell migration (without
Matrigel coat) (a) and invasion (with Matrigel coat) (b) were measured as described in ‘Methods’. The effect of lead compound DTP (1–10 μM) or heparin
(100 μg/mL) on cell migration and invasion is demonstrated by representative photomicrographs (magnification: ×5) and the respective bar graphs. Data are
represented as mean ± S.E. *P < 0.05
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side Hydrolase ligand structures 1, 1.63 Å resolution)
[49]. The structure was loaded into MOE [50] and cor-
rected using the Structure Preparation tool before run-
ning Protonate 3D. The Site Finder tool identified the
active site containing Glu-343 and Glu-225 that were
identified as the catalytic nucleophile and acid-base of
Heparanase [45, 49]. Compound structures were loaded
into MOE and energy minimised before carrying out
rigid receptor docking (triangle matcher, London dG
Forcefield refinement, GBVI/WSA dG rescoring).
The 52 docked poses that included the three active
compounds DTP, HTP, and ITP did not appear to
explain the experimentally observed trend in SAR. How-
ever, docking results revealed a similar interaction pat-
tern between active compounds ITP and DTP, with
poses that interact favourably with both Asn-224 and
Asp-62 due to the triazolo-thiadiazole backbone (Fig. 5).
For compound HTP, this interaction profile was found
to be slightly less favourable, interacting instead with
Asn-224 and the active site acid-base Glu-343.
Although these compounds do not appear to be more
favourable than the other docked compunds, thepresence of iodine substituents found on all hit com-
pounds may preferentially lower the phenols’ pKA suffi-
ciently to allow for deprotonation of the ligands in
protein environment.
Discussion
Human heparanase is an endoglucuronidase that cleaves
heparan sulfate chains thereby regulating multiple bio-
logical activities that together enhance tumor growth,
metastasis and angiogenesis [7–10, 14, 32]. Heparanase
is expressed by most types of cancer and has emerged as
a valid target for anti-cancer therapy [8, 15]. Heparanase
represents a druggable target because: (i) there is only a
single enzymatically active heparanase expressed in
humans, (ii) the enzyme is present in low levels in nor-
mal tissues but dramatically elevated in tumors where it
is associated with poor prognosis and reduced postoper-
ative survival time, and (iii) heparanase deficient mice
appear normal [51]. Thus, properly designed heparanase
inhibitors will likely have few, if any, negative side
effects. Development of heparanase inhibitors has
focused predominantly on carbohydrate-based com-
pounds with heparin-like properties [8, 15, 44]. These
Fig. 5 Selected docked poses for active compounds DTP, HTP and ITP (a, b and c, respectively), showing similar active site interaction modes. DTP
and ITP are shown to interact with both Asn-224 and Asp-62 via the triazolo-thiadiazole backbone, and HTP is shown to interact with Asn-224 and the
active site acid-base Glu-343
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flank the enzyme active site of heparanase thereby inhi-
biting cleavage of heparan sulfate. Four different heparin
mimics are currently in clinical trials in human cancer
patients. However all of these mimics have the disadvan-
tage that they are not specific for heparanase and likely
interact with different heparin-binding proteins with un-
known consequences and off target effects [8, 15].
Therefore, even if they prove efficacious in patients it
will be impossible to attribute their effect solely to
heparanase inhibition. In addition three of the four
mimics are heterogeneous in their structure adding
further to their uncertainty as viable drugs for use in
humans [8]. A number of heparanase-inhibiting small
molecules were reported [8, 16, 22], but none entered
clinical testing.
Heparanase expressed in cancer cells and cells of the
tumor microenvironment provides a most appropriate
therapeutic molecular target and could serve a decisive
role in cancer regime. In addition to remodeling of
ECM, human heparanase regulates multiple signaling
cascades involved in tumor cell survival, angiogenesis
and metastasis [7, 8, 14, 15, 44, 52]. The positive
correlation of heparanase with progression of malignan-
cies makes it an attractive target in the treatment of
cancer. It is hoped that our identification of a leadmolecule and the recently resolved crystal structure of
the heparanase protein [49] will accelerate rational de-
sign of heparanase-inhibiting small molecules endowed
with considerably improved binding affinity, specificity,
pharmacokinetics and efficacy in xenograft cancer
models. Selected molecules exerting little or no side ef-
fects will then be examined for oral availability and anti
cancer effect in combination with currently available
treatments, applying patient derived xenograft models
and, at a later stage, animal models of other diseases
shown to be causally related to heparanase [53–58].
Conclusions
In a search for small molecule inhibitors that can inter-
fere with the catalytic activity of human heparanase, we
report the synthesis and biological evaluation of a library
of synthetic small molecules and identification of
triazolo-thiadiazole derivative as a potent inhibitor of
human heparanase. The identified lead structure dis-
played antiproliferative activity and suppressed the mi-
gration and invasion of cancer cells in correlation with
inhibition of heparanase enzymatic activity. Further
development of this novel class of heparanase inhibitors
and optimization to maximize their affinity, pharmaco-
kinetics and oral availability will provide a unique
opportunity for development of innovative anti-cancer
Baburajeev et al. BMC Cancer  (2017) 17:235 Page 12 of 14therapeutics. Moreover, because heparanase helps drive
the progression of other diseases (e.g., diabetes, diabetic
nephropathy, arthritis, colitis, sepsis, atherosclerosis)
[53–58], these drugs hold potential to impact public
health.
Additional file
Additional file 1: Table S1. Optimisation of mol% of SCe catalyst, and
selection of medium for cyclization reaction. To optimize the reaction
conditions for the synthesis of novel 1,2,4-triazolo-1,3,4-thiadiazoles, the reaction
was performed in combination of 4-amino-5-phenyl-4 h-1,2,4-triazole-3-thiol
and 3-oxo-3-(p-tolyl)propanoic acid as a model reaction in different
concentrations of SCe and solvent. The optimal system for cyclization was
20 mol% of SCe in DMF. Table S2. Evaluation of the reuse of SCe for cyclization
reaction. The recyclability of the SCe system was evaluated by employing 4-
amino-5-phenyl-4 h-1,2,4-triazole-3-thiol with 3-oxo-3-(p-tolyl)propanoic acid to
yield 2-(3-Phenyl-[1, 2, 4]triazolo[3,4-b][1, 3, 4]thiadiazol-6yl)-1-p-tolylethanone.
The catalyst was removed by filtration after each run and thoroughly washed
with acetone, dried and activated at 823 K and taken for the next cycle. There
was a significant reduction in the yield of the product after the second run
using SCe. Figure S1. Spectral data. Scanned copy of 1H NMR, 13C NMR, and
mass spectra of the indicated compounds. (DOCX 4202 kb)
Abbreviations
BSA: Bovine serum albumin; DMEM: Dulbecco’s Modified Eagle Medium;
DTP: 2,4-Diiodo-6-(3-phenyl-[1, 2, 4]triazolo[3,4-b][1, 3, 4]thiadiazol-6yl)phenol;
ECM: Extracellular matrix; HGF: Hepatocyte growth factor; HS: Heparan Sulfate;
HSPG: heparan sulphate proteolglycan; HTP: 2-Hydroxy-3,5-diiodo-N-(3-phenyl-5-
thioxo-1H-1,2,4-triazol-4(5H)-yl)benzamide; ITP: 4-Iodo-2-(3-phenyl-[1, 2,
4]triazolo[3,4b][1, 3, 4]thiadiazol-6-yl)phenol.; LLC: Lewis lung carcinoma;
MOE: Molecular operating environment; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide; NMR: Nuclear magnetic resonance; OD: Optical
density; SAR: Structural activity relationship; SCe: sulphated ceria; TLC: Thin layer
chromatography; VEGF: Vascular endothelial growth factor
Acknowledgements
CPB thanks S. Jayasree for her guidance in synthesizing the catalyst. IV thanks
S. Feld for excellent technical assistance.
Funding
This research was supported by the Israel Science Foundation (ISF) and the
University Grants Commission (UGC) India, awarded to IV and KSR within the
ISF-UGC joint research program framework (grant No. 2277/15). The research
was also supported by University Grants Commission (41-257-2012-SR), Vision
Group Science and Technology, Department of Science and Technology (NO.
SR/FT/LS-142/2012) to Basappa. KSR thanks DST Indo-Korea [INT/Indo-Korea/
122/2011-12] and Institution of Excellence, University of Mysore for financial
support. CDM thanks the University of Mysore for Department of Science and
Technology-Promotion of University Research and Scientific Excellence (DST-
PURSE) Research Associate fellowship. IV is a research Professor of the Israel
Cancer Research Fund (ICRF). The funding agencies did not participate in the
design of the study and collection, analysis and interpretation of data and in
writing the manuscript.
Availability of data and materials
All data generated or analyses during this study are included in this article
and its Additional file 1.
Authors’ contributions
CPB, CDM, SR, DJM, JEF, UB and B carried out the chemistry, biological and
molecular studies. CDM, AB, IV, B and KSR interpreted the results and assisted
in manuscript preparation. AB, IV, B and KSR provided the tools, reagents for
research and prepared the manuscript. All authors read and approved the
final manuscript.
Competing interests
The authors declare that they have no competing interests.Ethics approval and consent to participate
This study does not involve animal studies and human data.
Consent for publication
Not applicable.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Laboratory of Chemical Biology, Department of Chemistry, Bangalore
University, Central College Campus, Palace Road, Bangalore 560001, India.
2Department of Studies in Chemistry, University of Mysore, Manasagangotri,
Mysore 570006, India. 3Department of Studies in Molecular Biology,
University of Mysore, Manasagangotri, Mysore 570006, India.
4Adichunchanagiri Institute for Molecular Medicine, BG Nagara, Nagamangala
Taluk, Mandya district-571448, India. 5Centre for Molecular Informatics,
Department of Chemistry, University of Cambridge, Lensfield Road,
Cambridge, UK. 6Cancer and Vascular Biology Research Center, the Bruce
Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Received: 25 February 2016 Accepted: 22 March 2017
References
1. Lu P, Takai K, Weaver VM, Werb Z. Extracellular Matrix Degradation and
Remodeling in Development and Disease. Cold Spring Harb Perspect Biol.
2011; 3(12):10.1101/cshperspect.a005058 a005058.
2. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M.
Functions of cell surface heparan sulfate proteoglycans. Ann Review Biochem.
1999;68:729–77.
3. Iozzo RV, Sanderson RD. Proteoglycans in cancer biology, tumour
microenvironment and angiogenesis. J Cell Mol Med. 2011;15(5):1013–31.
4. McKenzie EA. Heparanase: a target for drug discovery in cancer and
inflammation. Brit J Pharmacol. 2007;151(1):1–14.
5. Li JP, Vlodavsky I. Heparin, heparan sulfate and heparanase in inflammatory
reactions. Thromb Haemost. 2009;102(5):823–8.
6. Peterson SB, Liu J. Multi-faceted substrate specificity of heparanase. Matrix
Biol. 2013;32(5):223–7.
7. Arvatz G, Shafat I, Levy-Adam F, Ilan N, Vlodavsky I. The heparanase system
and tumor metastasis: is heparanase the seed and soil? Cancer Metastasis
Rev. 2011;30(2):253–68.
8. Rivara S, Milazzo FM, Giannini G. Heparanase: a rainbow pharmacological
target associated to multiple pathologies including rare diseases. Fut Med
Chem. 2016;8(6):647–80.
9. Vlodavsky I, Beckhove P, Lerner I, Pisano C, Meirovitz A, Ilan N, Elkin M.
Significance of heparanase in cancer and inflammation. Cancer
Microenviron. 2012;5(2):115–32.
10. Vreys V, David G. Mammalian heparanase: what is the message? J Cellular
Mol Med. 2007;11(3):427–52.
11. Zetser A, Bashenko Y, Edovitsky E, Levy-Adam F, Vlodavsky I, Ilan N. Heparanase
induces vascular endothelial growth factor expression: correlation with p38
phosphorylation levels and Src activation. Cancer Res. 2006;66(3):1455–63.
12. Ramani VC, Yang Y, Ren Y, Nan L, Sanderson RD. Heparanase plays a dual
role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF
expression and activity. J Biol Chem. 2011;286(8):6490–9.
13. Purushothaman A, Chen L, Yang Y, Sanderson RD. Heparanase stimulation
of protease expression implicates it as a master regulator of the aggressive
tumor phenotype in myeloma. J Biol Chem. 2008;283(47):32628–36.
14. Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of
heparanase in cancer metastasis and angiogenesis. Int J Biochem & Cell Biol.
2006;38(12):2018–39.
15. Pisano C, Vlodavsky I, Ilan N, Zunino F. The potential of heparanase as a
therapeutic target in cancer. Biochem Pharmacol. 2014;89(1):12–9.
16. Simizu S, Ishida K, Osada H. Heparanase as a molecular target of cancer
chemotherapy. Cancer Sci. 2004;95(7):553–8.
17. Khasraw M, Pavlakis N, McCowatt S, Underhill C, Begbie S, de Souza P,
Boyce A, Parnis F, Lim V, Harvie R, et al. Multicentre phase I/II study of
PI-88, a heparanase inhibitor in combination with docetaxel in patients
Baburajeev et al. BMC Cancer  (2017) 17:235 Page 13 of 14with metastatic castrate-resistant prostate cancer. Annals Oncol.
2010;21(6):1302–7.
18. https://clinicaltrials.gov/ct2/show/record/NCT01402908.
19. Dredge K, Hammond E, Handley P, Gonda TJ, Smith MT, Vincent C, Brandt
R, Ferro V, Bytheway I. PG545, a dual heparanase and angiogenesis inhibitor,
induces potent anti-tumour and anti-metastatic efficacy in preclinical
models. Br J Cancer. 2011;104(4):635–42.
20. Ritchie JP, Ramani VC, Ren Y, Naggi A, Torri G, Casu B, Penco S, Pisano C,
Carminati P, Tortoreto M, et al. SST0001, a chemically modified heparin,
inhibits myeloma growth and angiogenesis via disruption of the
heparanase/syndecan-1 axis. Clin Cancer Res. 2011;17(6):1382–93.
21. Zhou H, Roy S, Cochran E, Zouaoui R, Chu CL, Duffner J, Zhao G, Smith S,
Galcheva-Gargova Z, Karlgren J, et al. M402, a Novel Heparan Sulfate
Mimetic, Targets Multiple Pathways Implicated in Tumor Progression and
Metastasis. PLoS One. 2011;6(6):e21106.
22. Xu Y-J, Miao H-Q, Pan W, Navarro EC, Tonra JR, Mitelman S, Camara MM,
Deevi DS, Kiselyov AS, Kussie P, et al. N-(4-{[4-(1H-Benzoimidazol-2-yl)-
arylamino]-methyl}-phenyl)-benzamide derivatives as small molecule
heparanase inhibitors. Bioorganic & Med Chem Lett. 2006;16(2):404–8.
23. Keerthy HK, Mohan CD, Sivaraman Siveen K, Fuchs JE, Rangappa S,
Sundaram MS, Li F, Girish KS, Sethi G. Basappa et al. Novel synthetic
biscoumarins target tumor necrosis factor-alpha in hepatocellular carcinoma
in vitro and in vivo. J Biol Chem. 2014;289(46):31879–90.
24. Bharathkumar H, Mohan CD, Ananda H, Fuchs JE, Li F, Rangappa S,
Surender M, Bulusu KC, Girish KS, Sethi G, et al. Microwave-assisted
synthesis, characterization and cytotoxic studies of novel estrogen receptor
alpha ligands towards human breast cancer cells. Bioorganic & Med Chem
Lett. 2015;25(8):1804–7.
25. Rakesh KS, Jagadish S, Vinayaka AC, Hemshekhar M, Paul M, Thushara RM,
Sundaram MS, Swaroop TR, Mohan CD, Basappa, et al. A new ibuprofen
derivative inhibits platelet aggregation and ROS mediated platelet
apoptosis. PloS one. 2014;9(9):107182.
26. Roopashree R, Mohan CD, Swaroop TR, Jagadish S, Raghava B, Balaji KS,
Jayarama S. Basappa, Rangappa KS. Novel synthetic bisbenzimidazole that
targets angiogenesis in Ehrlich ascites carcinoma bearing mice. Bioorganic
& Med Chem Lett. 2015;25(12):2589–93.
27. Keerthy HK, Garg M, Mohan CD, Madan V, Kanojia D, Shobith R,
Nanjundaswamy S, Mason DJ, Bender A, Basappa, et al. Synthesis and
characterization of novel 2-amino-chromene-nitriles that target Bcl-2 in
acute myeloid leukemia cell lines. PLoS One. 2014;9(9):e107118.
28. Mohan CD, Srinivasa V, Rangappa S, Mervin L, Mohan S, Paricharak S, Baday S,
Li F, Shanmugam MK, Chinnathambi A, et al. Trisubstituted-Imidazoles Induce
Apoptosis in Human Breast Cancer Cells by Targeting the Oncogenic PI3K/Akt/
mTOR Signaling Pathway. PLoS One. 2016;11(4):e0153155.
29. Baburajeev CP, Mohan CD, Patil GS, Rangappa S, Pandey V, Sebastian A, Fuchs
JE, Bender A, Lobie PE. Basappa et al. Nano-cuprous oxide catalyzed one-pot
synthesis of a carbazole-based STAT3 inhibitor: a facile approach via
intramolecular C-N bond formation reactions. RSC Adv. 2016;6(43):36775–85.
30. Blich M, Golan A, Arvatz G, Sebbag A, Shafat I, Sabo E, Cohen-Kaplan V,
Petcherski S, Avniel-Polak S, Eitan A, et al. Macrophage activation by
heparanase is mediated by TLR-2 and TLR-4 and associates with plaque
progression. Arteriosclerosis Thromb & Vascular Biol. 2013;33(2):e56–65.
31. Hammond E, Li CP, Ferro V. Development of a colorimetric assay for
heparanase activity suitable for kinetic analysis and inhibitor screening. Anal
Biochem. 2010;396(1):112–6.
32. Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, Ishai-Michaeli R,
Bitan M, Pappo O, Peretz T, Michal I, et al. Mammalian heparanase: gene
cloning, expression and function in tumor progression and metastasis.
Nature Med. 1999;5(7):793–802.
33. Vlodavsky I. Preparation of Extracellular Matrices Produced by Cultured
Corneal Endothelial and PF-HR9 Endodermal Cells. Curr protocols Cell Biol.
1999; 10.14. 11-10.14. 14.
34. Bharathkumar H, Mohan CD, Rangappa S, Kang T, Keerthy HK, Fuchs JE,
Kwon NH, Bender A, Kim S. Basappa et al. Screening of quinoline, 1,3-
benzoxazine, and 1,3-oxazine-based small molecules against isolated
methionyl-tRNA synthetase and A549 and HCT116 cancer cells
including an in silico binding mode analysis. Organic & Biomol Chem.
2015;13(36):9381–7.
35. Ashwini N, Garg M, Mohan CD, Fuchs JE, Rangappa S, Anusha S, Swaroop
TR, Rakesh KS, Kanojia D, Madan V, et al. Synthesis of 1,2-benzisoxazole
tethered 1,2,3-triazoles that exhibit anticancer activity in acute myeloidleukemia cell lines by inhibiting histone deacetylases, and inducing p21 and
tubulin acetylation. Bioorg & Medicinal Chem. 2015;23(18):6157–65.
36. Baburajeev CP, Dhananjaya Mohan C, Ananda H, Rangappa S, Fuchs JE,
Jagadish S, Sivaraman Siveen K, Chinnathambi A, Ali Alharbi S, Zayed ME,
et al. Development of Novel Triazolo-Thiadiazoles from Heterogeneous
"Green" Catalysis as Protein Tyrosine Phosphatase 1B Inhibitors. Scientific
Reports. 2015;5:14195.
37. Mohan CD, Bharathkumar H, Bulusu KC, Pandey V, Rangappa S, Fuchs JE,
Shanmugam MK, Dai X, Li F, Deivasigamani A, et al. Development of a
novel azaspirane that targets the Janus kinase-signal transducer and
activator of transcription (STAT) pathway in hepatocellular carcinoma
in vitro and in vivo. J Biol Chem. 2014;289(49):34296–307.
38. Basappa M. S, Kavitha CV, Purushothaman A, Nevin KG, Sugahara K,
Rangappa KS. A small oxazine compound as an anti-tumor agent: a novel
pyranoside mimetic that binds to VEGF, HB-EGF, and TNF-alpha. Cancer Lett.
2010;297(2):231–43.
39. Sulaiman NB, Mohan CD, Basappa S, Pandey V, Rangappa S, Bharathkumar
H, Kumar AP, Lobie PE, Rangappa KS. An azaspirane derivative suppresses
growth and induces apoptosis of ER-positive and ER-negative breast cancer
cells through the modulation of JAK2/STAT3 signaling pathway. Int J Oncol.
2016;49(3):1221–9.
40. Hara M, Yoshida T, Takagaki A, Takata T, Kondo JN, Hayashi S, Domen K. A
carbon material as a strong protonic acid. Angew Chem Int Ed.
2004;43(22):2955–8.
41. Toda M, Takagaki A, Okamura M, Kondo JN, Hayashi S, Domen K, Hara M. Green
chemistry: biodiesel made with sugar catalyst. Nature. 2005;438(7065):178.
42. Mo X, López DE, Suwannakarn K, Liu Y, Lotero E, Goodwin JG, Lu C.
Activation and deactivation characteristics of sulfonated carbon catalysts. J
Catalysis. 2008;254(2):332–8.
43. Devi KS, Jayashree S. Modified ceria as a substitute for sulfuric acid in the liquid
phase nitration of toluene. React Kinet Mech Catal. 2013;108(1):183–92.
44. Vlodavsky I, Ilan N, Naggi A, Casu B. Heparanase: structure, biological
functions, and inhibition by heparin-derived mimetics of heparan sulfate.
Curr Pharm Des. 2007;13(20):2057–73.
45. Hulett MD, Hornby JR, Ohms SJ, Zuegg J, Freeman C, Gready JE, Parish CR.
Identification of active-site residues of the pro-metastatic endoglycosidase
heparanase. Biochemistry. 2000;39(51):15659–67.
46. Neelgundmath M, Dinesh KR, Mohan CD, Li F, Dai X, Siveen KS, Paricharak S,
Mason DJ, Fuchs JE, Sethi G, et al. Novel synthetic coumarins that targets
NF-kappaB in Hepatocellular carcinoma. Bioorganic & Med Chem Lett.
2015;25(4):893–7.
47. Anusha S, Anandakumar BS, Mohan CD, Nagabhushana GP, Priya BS,
Rangappa KS. Basappa, T CG. Preparation and use of combustion-derived
Bi2O3 for the synthesis of heterocycles with anti-cancer properties by
Suzuki-coupling reactions. RSC Adv. 2014;4(94):52181–8.
48. Anusha S, Mohan CD, Ananda H, Baburajeev CP, Rangappa S, Mathai J,
Fuchs JE, Li F, Shanmugam MK, Bender A, et al. Adamantyl-tethered-
biphenylic compounds induce apoptosis in cancer cells by targeting Bcl
homologs. Bioorg Med Chem Lett. 2016;26(3):1056–60.
49. Wu L, Viola CM, Brzozowski AM, Davies GJ. Structural characterization of
human heparanase reveals insights into substrate recognition. Nature Struc
Biol. 2015;22(12):1016–22.
50. C. C. G. Molecular Operating Environment version 2014.0901.
51. Zcharia E, Jia J, Zhang X, Baraz L, Lindahl U, Peretz T, Vlodavsky I, Li JP.
Newly generated heparanase knock-out mice unravel co-regulation of
heparanase and matrix metalloproteinases. PLoS One. 2009;4(4):e5181.
52. Fux L, Ilan N, Sanderson RD, Vlodavsky I. Heparanase: busy at the cell
surface. Trends Bioch Sci. 2009;34(10):511–9.
53. Parish CR, Freeman C, Ziolkowski AF, He YQ, Sutcliffe EL, Zafar A, Rao S,
Simeonovic CJ. Unexpected new roles for heparanase in Type 1 diabetes
and immune gene regulation. Matrix Biol. 2013;32(5):228–33.
54. Gil N, Goldberg R, Neuman T, Garsen M, Zcharia E, Rubinstein AM, van
Kuppevelt T, Meirovitz A, Pisano C, Li JP, et al. Heparanase is essential for
the development of diabetic nephropathy in mice. Diabetes.
2012;61(1):208–16.
55. Li RW, Freeman C, Yu D, Hindmarsh EJ, Tymms KE, Parish CR, Smith PN.
Dramatic regulation of heparanase activity and angiogenesis gene
expression in synovium from patients with rheumatoid arthritis. Arthritis &
Rheumatism. 2008;58(6):1590–600.
56. Lerner I, Hermano E, Zcharia E, Rodkin D, Bulvik R, Doviner V, Rubinstein AM,
Ishai-Michaeli R, Atzmon R, Sherman Y, et al. Heparanase powers a chronic
Baburajeev et al. BMC Cancer  (2017) 17:235 Page 14 of 14inflammatory circuit that promotes colitis-associated tumorigenesis in mice.
J Clin Invest. 2011;121(5):1709–21.
57. Schmidt EP, Yang Y, Janssen WJ, Gandjeva A, Perez MJ, Barthel L, Zemans
RL, Bowman JC, Koyanagi DE, Yunt ZX, et al. The pulmonary endothelial
glycocalyx regulates neutrophil adhesion and lung injury during
experimental sepsis. Nature Med. 2012;18(8):1217–23.
58. Vlodavsky I, Blich M, Li JP, Sanderson RD, Ilan N. Involvement of heparanase
in atherosclerosis and other vessel wall pathologies. Matrix Biol.
2013;32(5):241–51.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
